Thromb Haemost 1974; 31(02): 346-353
DOI: 10.1055/s-0038-1649169
Original Article
Schattauer GmbH

Blood Coagulation and Platelet-function Parameters before and during Parenteral Administration of Medroxyprogesterone Acetate as a Contraceptive Agent

G Baele
1   Departments of Medicine and Obstetrics, University Hospital, Ghent, Belgium
,
A Vermeulen
1   Departments of Medicine and Obstetrics, University Hospital, Ghent, Belgium
,
M Thiery
1   Departments of Medicine and Obstetrics, University Hospital, Ghent, Belgium
› Author Affiliations
Further Information

Publication History

Received 17 October 1973

Accepted 21 January 1974

Publication Date:
29 June 2018 (online)

Summary

The effects of medroxyprogesterone acetate on blood coagulation and platelet collagen aggregation were studied in nineteen women. After parenteral administration of the compound for 4 and 7 months, the activated partial thromboplastin time showed a significant decrease. The percentage of the prothrombin time test rose after 4 months, but not significantly after 7 months ; factor II decreased after 7 months of treatment. The reaction time during which no aggregation occurred after addition of a collagen suspension to a stirred platelet-rich plasma, was shorter after both 4 and 7 months of treatment. Other coagulation and platelet-function parameters were not altered. Although a trend toward hypercoagulability was detected, the changes were not the same as those reported for combined oral contraceptives.

 
  • References

  • 1 Åstedt B, Jeppson S, Pandolfi M. Fibrinolytic activity of veins during use of depot medroxyprogesterone acetate as a contraceptive. Fertility and Sterility 1972; a 23: 489
  • 2 Åstedt B. Fibrinolytic activity of veins during treatment with medroxypro-gesterone acetate. Acta obstetrica et gynecologica Scandinavica 1972; b 51: 283
  • 3 Bachmann F, Duckert F, Koller F. The Stuart-Prower factor assay and its clinical significance. Thrombosis et Diathesis Haemorrhagica 1958; 2: 24
  • 4 Baele G, Van den bogaeet P, Barbier F. Comparison of platelet aggregation in normal individuals and uremic patients with two different collagen preparations. Acta Medica Scandinavica 1971; suppl 525: 131
  • 5 Born G. V. R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927
  • 6 Brakman P, Sobrero A. J, Astrup T. Effects of different systemic contraceptives on blood fibrinolysis. American Journal of Obstetrics and Gynaecology 1970; 106: 187
  • 7 De Potter E, Offner-van den Berghe C. L’emploi d’un nouveau test de contrôle de la coagulation intrinsèque. Acta haematologica 1962; 28: 370
  • 8 Dugdale M, Masi A. T. Hormonal contraception and thromboembolic disease : effects of the oral contraceptives on hemostatic mechanism. A review of the literature. Journal of Chronic Diseases 1971; 23: 775
  • 9 Inman W. H. W, Vessey M. P, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the committee on safety of drugs. British Medical Journal 1970; 2: 203
  • 10 Mink I. B, Courey M. G, Moore R. H, Ambrus C. M, AmbrUs J. L. Progestational agents and blood coagulation. IV Changes induced by progestogen alone. American Journal of obstetrics and gynaecology 1972; 113: 739
  • 11 Nilsson I. M, Kullander S, Åstedt B. Coagulation and fibrinolytic studies during continuous use of low dose gestagen. Acta endocrinologica 1970; 65: 111
  • 12 O’Brien J. R. Platelet aggregation. Part II Some results from a new method of study. Journal of Clinical Pathology 1962; 15: 452
  • 13 Poller L, Thomson J. M, Tabiowo A, Priest C. M. Progesterone oral contraception and blood coagulation. British Medical Journal 1969; a 1: 554
  • 14 Poller L, Priest C. M, Thomson L. M. Platelet aggregation during oral contraception. British Medical Journal 1969; b 2: 273
  • 15 Poller L, Thomson J. M, Thomas W, Wray C. Blood clotting and platelet aggregation during oral progestogen contraception: a follow-up study. British Medical Journal 1971; 1: 705
  • 16 Poller L, Thomson J. M, Thomas P. W. Effects of progestogen oral contraception with norethisterone on blood clotting and platelets. British Medical Journal 1972; 2: 391
  • 17 Quick A. J, Stanley-Brown M, Bancroft F. W. A study of the coagulation defect in hemophilia and in jaundice. American Journal of Medical Sciences 1935; 190: 501
  • 18 Snedecor G. W. Statistical Methods. 5th Edition. Iowa State College Press.; 1956
  • 19 Soulier J. P, Larrieu M. J. Etude analytique des temps de Quick allongés. Dosages de prothrombine, de proconvertine et de proaccélérine. Sang 1952; 23: 549
  • 20 Soulier J. P, Larrieu M. J. Nouvelle méthode de diagnostic de l’hémophilie. Dosages des facteurs antihémophiliques A et B. Sang 1953; 24: 205
  • 21 Veemylen C, Verstraete M, Devreker R. A. A simple method for the instantaneous quantitation of fibrinogen: the FPT test. Acta clínica Belgica 1963; 18: 200
  • 22 Vessey M. P, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. British Medical Journal 1968; a 1: 199
  • 23 Vessey M. P, Weatherall J. A. C. Venous thromboembolic disease and the use of oral contraceptives. Lancet 1968; b 2: 94
  • 24 Wodzicki A. M, Coopland A. T. Chlormadinone acetate and its effect on the hemostatic mechanism. The Canadian Medical Association Journal 1972; 107: 38